cemsidomide + dexamethasone

**Cemsidomide + dexamethasone** is an oral investigational drug combination under active clinical development for relapsed/refractory multiple myeloma. It pairs cemsidomide (CFT7455), a next-generation MonoDAC cereblon-binding small-molecule degrader targeting Ikaros Family Zinc Finger Protein 1 and 3 (IKZF1/3), with dexamethasone, a synthetic glucocorticoid. - **Cemsidomide**: Binds cereblon, inducing ubiquitination and proteasomal degradation of IKZF1/3, leading to anti-myeloma effects via cell death, immune activation, and prevention of T-cell exhaustion. Designed to overcome resistance seen with earlier cereblon modulators (lenalidomide/pomalidomide), it demonstrates potent, selective, and sustained IKZF1/3 degradation[1][4][6]. - **Dexamethasone**: Potentiates anti-myeloma efficacy via glucocorticoid receptor–mediated apoptosis, inhibition of pro-inflammatory cytokines (notably interleukin-6), and direct cytotoxic effects in plasma cells[2][8].